Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Raphael Pharmaceutical Inc.

Get SEC filing alerts via email and in your feed for Raphael Pharmaceutical Inc.

RAPH

Raphael Pharmaceutical Inc.

About Raphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc. is a biotech company specializing in the discovery and development of cannabinoid-based therapies for autoimmune, inflammatory, and respiratory conditions. Its core focus is on developing CBD-derived drug candidates for rheumatoid arthritis, COVID-19-related hyperinflammation, and asthma. The company collaborates with research institutions, relies on third-party manufacturing, and aims to obtain regulatory approvals for innovative, plant-based medicines targeting unmet medical needs worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Raphael Pharmaceutical Inc.

1
1
Raphael Pharmaceutical Inc. Raphael Pharmaceutical Reports Q1 2026 Financial Results with $229,000 Net Loss

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Raphael Pharmaceutical Inc. Raphael Pharmaceutical Reports $1.28 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Raphael Pharmaceutical Inc. Raphael Pharmaceutical Reports $1M Net Loss and Launches New Product

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Raphael Pharmaceutical Inc. Raphael Pharmaceutical Reports $751,000 Net Loss, Launches New RA Treatment

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Raphael Pharmaceutical Inc. Raphael Pharmaceutical Reports Q1 2025 Financial Results with $429,000 Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Raphael Pharmaceutical Inc. Raphael Pharmaceutical Inc. Reports $1.52 Million Net Loss and Advances Clinical Research

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Raphael Pharmaceutical Inc. Raphael Pharmaceutical Reports Nine-Month Financial Results, Highlights Decreased Expenses and Losses

Via official filing (AI summary) | over 1 year ago | 0 comments